1 completed, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Neurotech Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) NT-503-3 ECT implantation, Eylea® injected intravitreally administered every 8 weeks - Macular Degeneration | Phase 1 / Phase 2 | Terminated | Neurotech Pharmaceuticals | 42 | 2014-09-01 | 2022-07-18 |
| Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel) NT-501 implant - Idiopathic Juxtafoveal Telangiectasia | Phase 1 | Completed | Neurotech Pharmaceuticals | 7 | 2011-05-01 | 2016-11-22 |
Idiopathic Juxtafoveal Retinal Telangiectasia (1) · Macular Degeneration (1)
United States (2) · Israel (1)
Charles Johnson, MB, ChB (1) · Weng Tao (1)